SCHEMBL6791929

SCHEMBL6791929

O=C1NC(=O)C(CSCc2ccccc2)N1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.51
GAA P10253 2/20 0.51
MAPT P10636 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
ATM Q13315 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
DDB1 Q16531 1/20 0.40
HDAC8 Q9BY41 2/20 0.40
ADAMTS4 O75173 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
CYP2C19 P33261 2/20 0.38
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
CASP1 P29466 1/20 0.37
HTT P42858 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12946013 1.00 CRBN (0.51) CRBNGAAMAPTNPC1RAB9A
SCHEMBL14357764 0.78 HDAC8 (0.57) CRBNGAADDB1HDAC8ADAMTS4
SCHEMBL1011632 0.78 HDAC8 (0.57) CRBNGAADDB1HDAC8ADAMTS4
SCHEMBL7457787 0.77 GAA (0.43) CRBNGAAMAPTNPC1RAB9A
SCHEMBL15974260 0.75 GAA (0.49) GAAL3MBTL1HDAC8ADAMTS4ADAMTS5
SCHEMBL6791007 0.75 GAA (0.49) GAAL3MBTL1HDAC8ADAMTS4ADAMTS5
SCHEMBL14398335 0.74 GAA (0.43) CRBNGAAMAPTNPC1RAB9A
SCHEMBL1598100 0.73 CRBN (0.49) CRBNGAAMAPTL3MBTL1DDB1
SCHEMBL12482199 0.73 L3MBTL1 (0.50) CRBNGAAMAPTNPC1RAB9A
SCHEMBL16903961 0.73 L3MBTL1 (0.50) CRBNGAAMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
US-5767140-A USEFUL FOR TREATING AIDS SOUTHERN RESEARCH INSTITUTE (US) 1998-06-16 US disclosed
EP-0660826-A4 5,5-DISUBSTITUTED HYDANTOINS. SOUTHERN RES INST (US) 1996-07-31 EP disclosed
EP-0660826-A1 5,5-DISUBSTITUTED HYDANTOINS SOUTHERN RESEARCH INSTITUTE (US) 1995-07-05 EP disclosed
WO-1994006775-A1 5,5-DISUBSTITUTED HYDANTOINS SOUTHERN RESEARCH INSTITUTE (US) 1994-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 CRBN 4722/4885GAA 274/4885MAPT 4179/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 CRBN 2960/4885GAA 408/4885MAPT 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.